Top

Published in:

01-10-2017 | Research Article

Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients

Authors: Fajiu Li, Jie Huang, Dongyuan Ji, Qinghua Meng, Chuanhai Wang, Shi Chen, Xiaojiang Wang, Zhiyang Zhu, Cheng Jiang, Yi Shi, Shuang Liu, Chenghong Li

Published in: Clinical and Translational Oncology | Issue 10/2017

Abstract

Purpose

Non-invasive methods of molecular profiling for non-small cell lung cancer (NSCLC) are useful for monitoring disease progression. The aim of the current study was to ascertain if transrenal DNA is sensitive for clinical correlation and EGFR detection in NSCLC patients.

Methods

160 patients at various stages of the disease participated and samples were collected prospectively at 2-month intervals. A baseline sample was taken before treatment commencement. To ascertain the sensitivity of transrenal DNA, we compared its results with plasma DNA. ddPCR was used to profile the urine and blood samples for key EGFR mutations.

Results

Using tumor tissues as references, our study showed good concordance in EGFR mutations with transrenal DNA before treatment. Results were highly matching in late-stage NSCLC patients, with stage III/IV patients yielding an agreement of more than 90%. The assay was also sensitive to detect early-stage patients after surgical procedures. Profiles were highly concordant with results derived from plasma DNA, demonstrating the specificity of transrenal DNA assays. Serial monitoring of these patients showed stable molecular signatures and correlated to different treatments. Survival analysis showed good prognostic utility for late-stage patients with high transrenal DNA variations and patients that acquired T790M mutation.

Conclusion

The study demonstrated the feasibility of using transrenal DNA in mutation profiling for different stages of NSCLC patients. It highlights the importance of continual monitoring and has potential clinical utility in the clinical management of NSCLC.

Available only for authorised users

Li T, Kung H-J, Mack PC, Gandara DR. Genotyping and genomic profiling of non–small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013;31(8):1039–49.CrossRefPubMedPubMedCentral

Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305(5687):1163–7.CrossRefPubMed

Arcila ME, Riely GJ, Zakowski MF, Kris MG, Ladanyi M, Pao W et al. Rebiopsy of patients (pts) with acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). J Clin Oncol. 2009;27(15S):8025

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500.CrossRefPubMed

Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucl Acids Res. 2010;38(18):6159–75.CrossRefPubMedPubMedCentral

Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–86.CrossRefPubMedPubMedCentral

Xu S, Lou F, Wu Y, Sun D-Q, Zhang J-B, Chen W, et al. Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients. Cancer Lett. 2016;370(2):324–31.CrossRefPubMed

Wei Z, Shah N, Deng C, Xiao X, Zhong T, Li X. Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the disease. Springerplus. 2016;5(1):531. doi:10.1186/s40064-016-2141-5.CrossRefPubMedPubMedCentral

Su Y-H, Wang M, Brenner DE, Ng A, Melkonyan H, Umansky S, et al. Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn. 2004;6(2):101–7.CrossRefPubMedPubMedCentral

10.

Fischbach FT, Dunning MB. A manual of laboratory and diagnostic tests. Philadelphia: Lippincott Williams & Wilkins; 2009.

11.

Gupta A, Bansal N, Houston B. Metabolomics of urinary tract infection: a new uroscope in town. Expert Rev Mol Diagn. 2012;12(4):361–9.CrossRefPubMed

12.

He J, Tan W, Ma J. Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer. Future Oncol. 2017;13(9):787–97.CrossRefPubMed

13.

Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol. 2012;7(1):115–21.CrossRefPubMed

14.

Zhu G, Ye X, Dong Z, Lu YC, Sun Y, Liu Y, et al. Highly sensitive droplet digital PCR method for detection of EGFR-activating mutations in plasma cell-free DNA from patients with advanced non-small cell lung cancer. J Mol Diagn. 2015;17(3):265–72. doi:10.1016/j.jmoldx.2015.01.004.CrossRefPubMed

15.

Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DWY, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136. doi:10.1126/scitranslmed.3003726.CrossRef

16.

Sozzi G, Roz L, Conte D, Mariani L, Andriani F, Lo Vullo S, et al. Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am J Respir Crit Care Med. 2009;179(1):69–74. doi:10.1164/rccm.200807-1068OC.CrossRefPubMed

17.

Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42. doi:10.1016/s1470-2045(11)70184-x.CrossRefPubMed

18.

Boch C, Kollmeier J, Roth A, Stephan-Falkenau S, Misch D, Grüning W, et al. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open. 2013;3(4):e002560. doi:10.1136/bmjopen-2013-002560.CrossRefPubMedPubMedCentral

19.

Wang X, Meng Q, Wang C, Li F, Zhu Z, Liu S, et al. Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression. Biomarkers. 2016;. doi:10.1080/1354750X.2016.1269202.

20.

Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–26.CrossRefPubMed

21.

Riediger AL, Dietz S, Schirmer U, Meister M, Heinzmann-Groth I, Schneider M, et al. Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients. Sci Rep. 2016;6:33505. doi:10.1038/srep33505.CrossRefPubMedPubMedCentral

22.

Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer. 2007;97(6):778–84. doi:10.1038/sj.bjc.6603949.CrossRefPubMedPubMedCentral

23.

Chen K-Z, Lou F, Yang F, Zhang J-B, Ye H, Chen W, et al. Circulating tumor DNA detection in early-stage non-small cell lung cancer patients by targeted sequencing. Sci Rep. 2016;6:31985. doi:10.1038/srep31985.CrossRefPubMedPubMedCentral

24.

Al-Kattan K, Sepsas E, Fountain SW, Townsend ER. Disease recurrence after resection for stage I lung cancer. Eur J Cardiothorac Surg. 1997;12(3):380–4.CrossRefPubMed

25.

Warton K, Mahon KL, Samimi G. Methylated circulating tumor DNA in blood: power in cancer prognosis and response. Endocr Relat Cancer. 2016;23(3):R157–71. doi:10.1530/ERC-15-0369.CrossRefPubMedPubMedCentral

26.

Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–90. doi:10.1038/nm.1789.CrossRefPubMed

27.

Sirera R, Bremnes RM, Cabrera A, Jantus-Lewintre E, Sanmartín E, Blasco A, et al. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J Thor Oncol. 2011;6(2):286–90.CrossRef

28.

Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73. doi:10.1371/journal.pmed.0020073.CrossRefPubMedPubMedCentral

29.

Yun C-H, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong K-K, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci. 2008;105(6):2070–5.CrossRefPubMedPubMedCentral

30.

Lee Y, Lee GK, Lee YS, Zhang W, Hwang JA, Nam BH, et al. Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations. Cancer. 2014;120(14):2090–8. doi:10.1002/cncr.28711.CrossRefPubMed

31.

Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY, Ni J, et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep. 2016;6:20913. doi:10.1038/srep20913.CrossRefPubMedPubMedCentral

32.

Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359(4):366–77. doi:10.1056/NEJMoa0800668.CrossRefPubMedPubMedCentral

Title: Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients
Authors: Fajiu Li
Jie Huang
Dongyuan Ji
Qinghua Meng
Chuanhai Wang
Shi Chen
Xiaojiang Wang
Zhiyang Zhu
Cheng Jiang
Yi Shi
Shuang Liu
Chenghong Li
Publication date: 01-10-2017
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 10/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1669-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2017

Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients

Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma

Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma

Micropapillary bladder cancer: a clinico-pathological characterization and treatment analysis

Age-based disparities in the use of total thyroidectomy for papillary thyroid carcinoma

Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival

Keynote webinar | Spotlight on antibody–drug conjugates in cancer